{"id":"NCT02846532","sponsor":"Janssen Research & Development, LLC","briefTitle":"Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure","officialTitle":"A Prospective, Open-Label, Active-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 to 8 Years of Age After the Fontan Procedure","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-16","primaryCompletion":"2020-07-16","completion":"2020-07-16","firstPosted":"2016-07-27","resultsPosted":"2022-03-28","lastUpdate":"2025-03-30"},"enrollment":112,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Thrombosis"],"interventions":[{"type":"DRUG","name":"Rivaroxaban","otherNames":[]},{"type":"DRUG","name":"Acetylsalicylic Acid","otherNames":[]}],"arms":[{"label":"Rivaroxaban","type":"EXPERIMENTAL"},{"label":"Acetylsalicylic Acid","type":"EXPERIMENTAL"}],"summary":"The Purpose of this study is to characterize the single and multiple-dose pharmacokinetic (PK) and pharmacokinetic/pharmacodynamic (PK/ PD) profiles after oral rivaroxaban therapy administered to pediatric participants 2 to 8 years of age with single ventricle physiology who have completed the Fontan procedure within 4 months prior to enrollment (Part A) and to evaluate the safety and efficacy of rivaroxaban, administered twice daily (exposure matched to rivaroxaban 10 milligram \\[mg\\] once daily in adults) compared to acetylsalicylic acid (ASA), given once daily (approximately 5 milligram per kilogram \\[mg/kg\\]) for thromboprophylaxis in pediatric participants 2 to 8 years of age with single ventricle physiology who have completed the Fontan procedure within 4 months prior to enrollment.","primaryOutcome":{"measure":"Percentage of Participants With Any Thrombotic Event (Venous or Arterial and Symptomatic or Asymptomatic)","timeFrame":"Up to 12 months","effectByArm":[{"arm":"Rivaroxaban (Part A)","deltaMin":8.3,"sd":null},{"arm":"Rivaroxaban (Part B)","deltaMin":1.6,"sd":null},{"arm":"Aspirin (Part B)","deltaMin":8.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":42,"countries":["United States","Argentina","Belgium","Brazil","Canada","Japan","Malaysia","Mexico","Netherlands","Spain"]},"refs":{"pmids":["34558312"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217051&amp;parentIdentifier=CR108075&amp;attachmentIdentifier=ecc7606d-69c9-4747-8c64-2f0ad414eacd&amp;fileName=2015-002610-76-_Receipt.png&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":12},"commonTop":["Pyrexia","Nasopharyngitis","Upper Respiratory Tract Infection","Cough","Vomiting"]}}